

Aytu BioScience to Present at 2016 BioPharm America Conference

ENGLEWOOD, Colo., Sept. 6, 2016 — Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Chief Operating Officer Jarrett Disbrow will present at the 2016 BioPharm America Conference, to be held September 13-15, 2016, at the Boston Marriott Copley Place in Boston, MA.

The conference offers strategic partnership opportunities and a platform to network with innovative world leaders across the biotech, finance and pharma industries. Mr. Disbrow will be available to meet with interested companies and investors who are registered to attend the conference.

Conference Details:

Event: 2016 BioPharm America Conference

Date: September 14, 2016

Time: 3:30 p.m. (Eastern Time)

Location: Boston Marriott Copley Place, Boston

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The Company currently markets three products: Natesto[®], the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or “Low T”), ProstaScint[®] (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging, and Primsol[®] (trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Additionally, Aytu is developing MiOXSYS™, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu’s strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets. For more information, visit <http://aytubio.com>.

For Investors & Media:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664

Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

To view the original version on PR Newswire,
visit:<http://www.prnewswire.com/news-releases/aytu-bioscience-to-present-at-2016-biopharm-america-conference-300322320.html>

SOURCE Aytu BioScience, Inc.